Professional
Added to YB: 2025-03-31
Pitch date: 2025-03-26
SMMT [bullish]
Summit Therapeutics Inc.
+65.65%
current return
Author Info
No bio for this author
Company Info
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
Market Cap
$18.2B
Pitch Price
$20.06
Price Target
35.00 (+28%)
Dividend
N/A
Sector
Biotechnology
Category
growth
Citibank Upgrades Summit Therapeutics (SMMT) to Buy, Raises Target to $35
SMMT (upgrade): Citibank upgrades to Buy, $35 PT (from $23). 70% chance of favorable OS readout in HARMONi-2 trial for ivonescimab at YE25. If successful, could be paradigm-shifting therapy in NSCLC, ushering new era in immunotherapy. Analysts see strong upside potential.
Read full article (1 min)